	US 12,390,428 B2
	Bupropion and dextromethorphan for reduction of suicide risk in depression patients
Herriot Tabuteau, New York, NY (US)
Assigned to ANTECIP BIOVENTURES II LLC, New York, NY (US)
Filed by ANTECIP BIOVENTURES II LLC, New York, NY (US)
Filed on Dec. 27, 2023, as Appl. No. 18/397,220.
Application 18/397,220 is a continuation of application No. 18/323,714, filed on May 25, 2023, granted, now 11,896,563.
Application 18/323,714 is a continuation of application No. PCT/US2021/061492, filed on Dec. 1, 2021.
Claims priority of provisional application 63/120,160, filed on Dec. 1, 2020.
Claims priority of provisional application 63/120,672, filed on Dec. 2, 2020.
Claims priority of provisional application 63/122,902, filed on Dec. 8, 2020.
Prior Publication US 2024/0390297 A1, Nov. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/137 (2006.01); A61K 31/485 (2006.01); A61P 25/24 (2006.01)

CPC A61K 31/137 (2013.01) [A61K 31/485 (2013.01); A61P 25/24 (2018.01)]

17 Claims

1. A method of treating depression and reducing risk of suicide, comprising selecting a human being suffering from major depressive disorder and having a score of 3 or greater on the Suicidality Item of the Montgomery-Åsberg Depression Rating Scale (MADRS-SI) and a score of at least 35 on the Montgomery-Åsberg Depression Rating Scale (MADRS), and administering a combination of about 90 mg to about 120 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, and about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan, to a human being; wherein the combination is administered twice a day to the human being.